6/3/2022 4:39:18 PM
Wedbush Cuts Turning Point Therapeutics (TPTX) To Neutral From Outperform With $76 Up From $61 Price Target
6/3/2022 8:53:14 AM
Bristol Myers Squibb To Acquire Turning Point Therapeutics For $76.00/shr
10/7/2021 7:07:32 AM
Turning Point Therapeutics Presents Updated Data For Repotrectinib And Elzovantinib At 2021 AACR-NCI-EORTC Conference
5/17/2021 9:27:47 AM
Turning Point Therapeutics Names Kumar Srinivasan As EVP, Chief Business Officer